You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 63 No. 1, January 2006 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Article
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (10)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Genetics
 •Genetic Disorders
 •Neurology
 •Cognitive Disorders
 •Dementias
 •Psychiatry, Other
 •Alert me on articles by topic

Apolipoprotein E Genotype and Age-Related Myelin Breakdown in Healthy Individuals

Implications for Cognitive Decline and Dementia

George Bartzokis, MD; Po H. Lu, PsyD; Daniel H. Geschwind, MD; Nancy Edwards, MA; Jim Mintz, PhD; Jeffrey L. Cummings, MD

Arch Gen Psychiatry. 2006;63:63-72.

Context  Apolipoprotein E (APOE) genotype is the most influential Alzheimer disease (AD) risk factor after advanced age. The APOE4 alleles decrease and the APOE2 alleles increase age at onset of AD. Human and nonhuman primate data suggest that in midlife, the structural integrity of myelin sheaths begins breaking down, with an accelerating age-related trajectory most evident in the brain's later-myelinating association regions. This may result in a progressive "disconnection" of widely distributed neural networks that may underlie the age risk factor for AD.

Objective  To assess, using magnetic resonance imaging, whether the shift in age at onset of AD observed with the APOE genotype is associated with the trajectory of age-related myelin breakdown.

Design  Cross-sectional.

Setting  Metropolitan university medical center.

Participants  Healthy individuals (N = 104) aged 55 to 75 years who underwent genotyping for APOE.

Main Outcome Measures  Calculated transverse relaxation rates, an indirect measure of white matter structural integrity, for late-myelinating frontal lobe white matter (Fwm) and early- and later-myelinating regions of the corpus callosum, the splenium (Swm) and the genu (Gwm).

Results  The presence of the protective APOE2 allele was associated with significantly higher relaxation rates in Fwm and Gwm but not in Swm. Furthermore, APOE status impacted the trajectory of age-related myelin breakdown in late-myelinating regions (Fwm and Gwm) but not in Swm. In Fwm and Gwm, APOE4+ individuals had a steeper slope of decline in relaxation rates with age than APOE2+ individuals; those with APOE3/3 alleles had an intermediate slope.

Conclusions  In later-myelinating regions, the severity and rate of myelin breakdown in healthy older individuals are associated with APOE status and support the hypothesis that this process may contribute to age at onset of AD. Combining APOE status with noninvasive measures of myelin breakdown may be useful in assessing treatment strategies for the primary prevention of AD.


Author Affiliations: Department of Neurology (Drs Bartzokis, Lu, Geschwind, and Cummings and Ms Edwards), Laboratory of Neuroimaging, Division of Brain Mapping, Department of Neurology (Dr Bartzokis), and Department of Psychiatry and Biobehavioral Sciences (Drs Mintz and Cummings), The David Geffen School of Medicine at UCLA, Los Angeles, Calif; Department of Psychiatry, VA Greater Los Angeles Healthcare System, West Los Angeles (Drs Bartzokis, Lu, and Mintz and Ms Edwards).



THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Diffusion tensor imaging in preclinical and presymptomatic carriers of familial Alzheimer's disease mutations
Ringman et al.
Brain 2007;130:1767-1776.
ABSTRACT | FULL TEXT  

Gene Variant May Hasten Development of Alzheimer's
Arehart-Treichel
Psychiatr. News 2006;41:17-17.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2006 American Medical Association. All Rights Reserved.